Walleye Capital LLC Coherus Bio Sciences, Inc. Transaction History

Walleye Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.58 - $2.51 $77,892 - $123,740	-49,299 Reduced 63.66%	28,137 $48,000
Q1 2024 May 15, 2024	SELL	$2.02 - $3.14 $45,690 - $71,023	-22,619 Reduced 22.61%	77,436 $185,000
Q4 2023 Feb 14, 2024	BUY	$1.59 - $3.85 $92,382 - $223,692	58,102 Added 138.49%	100,055 $333,000
Q3 2023 Nov 14, 2023	BUY	$3.74 - $5.45 $79,658 - $116,079	21,299 Added 103.12%	41,953 $156,000
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $78,278 - $171,428	20,654 New	20,654 $88,000
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $93,697 - $165,822	16,467 New	16,467 $130,000

132

76.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $91.7M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.